Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 15/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.51 |
| ▸ | FLT3 | P36888 | 6/20 | 0.51 |
| ▸ | MET | P08581 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574543 | 0.88 | KDR (0.54) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL573555 | 0.88 | AXL (0.56) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL573627 | 0.88 | CSF1R (0.55) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL2904390 | 0.85 | AXL (0.53) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL574370 | 0.85 | CSF1R (0.51) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL574371 | 0.85 | AXL (0.56) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL2951242 | 0.84 | AXL (0.54) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL573432 | 0.83 | AXL (0.54) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL2926583 | 0.82 | AXL (0.53) | AXLCSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL574312 | 0.82 | KDR (0.56) | AXLCSF1RPDGFRAPDGFRBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | claimed |
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2148677-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008131276-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | AXL 233/4885CSF1R 80/4885PDGFRA 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.